Recipharm’s new CEO on ‘fast and furious’ changes, with eyes on GLP-1, biologics manufacturing
Another sign that the post-pandemic reshaping of the CDMO industry isn't over came Tuesday as one of the sector’s most powerful companies, Recipharm, sold off seven of its manufacturing and development facilities in Europe to Blue Wolf Capital.
HOLMES CHAPEL, UK / ACCESSWIRE / April 2, 2024 / Bespak today announced the completion of the transaction to separate Recipharm's former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company. Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.
Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm
Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
Recipharm harmonizes its global quality operations with Veeva Vault Quality
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas` LNP formulations
Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
Recipharm CEO Marc Funk is stepping down at the beginning of next year, and a former Nestlé executive is set to take over as chief executive as the CDMO prepares to spin off its inhaler business.
Recipharm CEO Marc Funk anticipates 2024 to be just as challenging for CDMOs in terms of finding opportunities for growth due to wider economic challenges.